MARKET WIRESeeking Alpha • 19h ago
BillionToOne: Molecular Diagnostics Stock With Strong Quality And GARP Credentials (BLLN)Seeking Alpha report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
Why BLLN Stock slipped -1.32% Today — RQD Quant Desk Flash
$113.32 -1.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $113.32
BillionToOne Inc. (BLLN) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (68% profit margin, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B- • BUY
Cap $5.35B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BLLN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BLLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, BillionToOne Inc. (NASDAQ: BLLN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $113.32 (-1.32% 1D, market cap $5.35B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, BLLN ranks #76 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BLLN compare to CON and RDNT in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), BLLN carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of 68.3%, and ROIC of 2.9%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.15B) and RDNT (RadNet Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BLLN?
▼
Per BLLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070849), BillionToOne Inc. generated $305.1M in revenue (+100.0% YoY), $7.5M in net income, and $15.7M in free cash flow against $632.7M in total assets and $57.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $113.32 (+0.00%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 5.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BLLN)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY BLLN SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)
Altman Z-Score 22.24 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (21% of score)
20D Institutional Volume Accumulation (±10.3% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)
Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$97.88+6.9% Next Q
62
Q2 (-2Q)Grade C+$104.67+8.9% Next Q
65
Q3 (-1Q)Grade B-$114.00-0.6% Next Q
67
CurrentGrade B-$113.32+6.6% Hist 90D α
70
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the BLLN Bull Thesis Could Fail
Even with a 70/100 (B-) score, BLLN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) — any gross margin slip below 65.8% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($104.83) or 200D SMA ($96.81) invalidates the momentum regime and cuts Target Base ($119.44) toward Bear Floor ($92.92).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLLN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BLLN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BLLN Stock slipped -1.32% Today — RQD Quant Desk Flash
BillionToOne Inc. (BLLN) slipped -1.32% to $113.32, trading at 58% of its 52-week range ($61.96 – $150.44). High-quality cash engine (68% profit margin, 3% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 58% of its 52-week range ($61.96 – $150.44) with RSI-14 at 58.4 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.3% around $113.32 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 68.3% gross margin and $15.7M annual free cash flow.
Live BLLN Headlines & Catalysts
MARKET WIREInvesting.com • 22h ago
BillionToOne CTO David Tsao sells $2.16m in sharesInvesting.com report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
After a $4.45M sale, Atay proposes selling more BillionToOne (BLLN) shares.Stock Titan report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
RISK WATCHMarketBeat • 1d ago
Billiontoone (NASDAQ:BLLN) Stock Falls 6.5% - What's Next?MarketBeat report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
BillionToOne (NasdaqGS:BLLN) Stock Forecast & Analyst PredictionsSimply Wall St report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
Billiontoone (NASDAQ:BLLN) Stock Jumps 3.5% - Here's What HappenedMarketBeat report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A 20,000-share option exercise accompanies a proposed sale by a BillionToOne (NASDAQ: BLLN) officer.Stock Titan report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share (BLLN)Seeking Alpha report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Baxter International (BAX) Q3 Earnings and Revenues Surpass EstimatesBaxter (BAX) delivered earnings and revenue surprises of +13.73% and +2.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
MARKET WIREYahoo • 5d ago
Top Specialty Lab Stocks to Watch This Earnings Season, According to BTIGInvesting.com-- Several specialty lab companies are set to report third-quarter results in early November, with analysts at BTIG outlining key metrics and expectations for the sector’s leading names. The firm has identif
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (BLLN Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BLLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.13%⚡ TESTING RESISTANCE
2026-11-03O $114.8H $114.8L $113.3C $113.3VOL 468.5K
RES: $116.6SUP: $91.51SMA50: $104.8SMA200: $96.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BLLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BLLN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BLLN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLLN)
Health Care Rank #76 of 1016
⚔️ CON vs BLLN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BLLN vs. CON, RDNT, CDNA, GRAL)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, BillionToOne Inc. (BLLN) ranks #76 by composite RQD confidence (70/100, grade B-) and #154 by equity capitalization ($5.35B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. CDNA currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with BLLN at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BLLN
ACTIVE
BillionToOne Inc. | B- | 70/100 | — | 68.3% | 2.9% | -1.32% | $5.35B | Benchmark Subject |
| CON Concentra Group Holdings Parent Inc. | C+ | 68/100 | 31.6x | — | 19.7% | -2.11% | $5.15B | /con-vs-blln → |
| RDNT RadNet Inc. | D+ | 57/100 | — | — | 3.5% | -0.22% | $5.78B | /rdnt-vs-blln → |
| CDNA CareDx Inc. | B- | 71/100 | — | — | -8.2% | +22.22% | $4.59B | /cdna-vs-blln → |
| GRAL GRAIL Inc. | D+ | 54/100 | — | — | -18.0% | -9.75% | $6.41B | /gral-vs-blln → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002070849In its most recent audited fiscal period (FY2025, filed 2025-12-31), BillionToOne Inc. (BLLN) reported GAAP revenue of $305.1M (+100.0% vs. FY2024 revenue of $152.6M , and +325.4% cumulative change since FY2023) , GAAP net income of $7.5M, operating cash flow of $24.6M, and free cash flow of $15.7M (+133.6% YoY). On the balance sheet, BLLN closed FY2025 with $632.7M in total assets against $57.2M in total debt (Altman Z-Score: 22.24, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $305.1M | $7.5M | $24.6M | $15.7M | $632.7M | $57.2M |
| FY2024 (FY) | 2024-12-31 | $152.6M | -$41.6M | -$41.4M | -$46.8M | $302.1M | $51.5M |
| FY2023 (FY) | 2023-12-31 | $71.7M | -$82.7M | -$53.7M | -$56.9M | $2.98B | $697.4M |
3. BLLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BLLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, BillionToOne Inc. (NASDAQ: BLLN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $113.32 (-1.32% 1D, market cap $5.35B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, BLLN ranks #76 in composite RQD confidence.
How does BLLN compare to CON and RDNT in the Health Care sector?
Within the Health Care sector (Medical Specialities), BLLN carries a Roarable B- (70/100 RQD), trailing P/E of N/A, gross margin of 68.3%, and ROIC of 2.9%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.15B) and RDNT (RadNet Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BLLN?
Per BLLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070849), BillionToOne Inc. generated $305.1M in revenue (+100.0% YoY), $7.5M in net income, and $15.7M in free cash flow against $632.7M in total assets and $57.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BLLN trading relative to its 50-day, 200-day, and 52-week technical levels?
BLLN last traded at $113.32 (-1.32% on volume of 468,452 shares), positioning the stock +8.10% above its 50-day simple moving average ($104.83) and +17.05% above its 200-day simple moving average ($96.81). Across its 52-week range of $61.96 to $150.44, BLLN sits at the 58.0% percentile with a 14-day RSI of 58.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.3% ($101.65 to $124.99).
BLLN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BLLN stock moving today?
Why BLLN Stock slipped -1.32% Today — RQD Quant Desk Flash. High-quality cash engine (68% profit margin, 3% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 70/100 (B-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BLLN — BillionToOne Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:20:15Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BLLN scores 71 out of 100 (letter grade B-, verdict "Roarable Buy — Sound Institutional Accumulation"). Across the five pillars: Fundamental Cash Engine 14/20 (ROIC 2.9%; FCF yield 0.29%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 8/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 15/20 (Beta 1.02; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 22.24; Piotroski F 9/9; Debt/Equity 0.12).
The strongest pillar is the forensic balance sheet, which indicates low leverage and strong financial-health screens. The weakest pillar is insider conviction, which the rating scores at 8/20 despite the recorded Form 4 activity in the news wire. The cash-engine pillar is moderate: the RQD rating reflects a low ROIC and FCF yield, which tempers the return profile even as revenue has grown. Investor implications: upside drivers appear to be institutional accumulation and balance-sheet strength; valuation tradeoffs are visible in the market data, where EV/EBITDA is 95 and FCF yield is 0.29%, implying the price already embeds substantial expectations relative to current cash generation. This is an educational reading of the rating, not personalized financial advice.
Business
BillionToOne Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Medical Specialities industry, per the profile section. The source data does not describe its products, customers, or revenue model. The reported margins are a gross margin of 68.3%, an operating margin of 5.3%, and a net margin of 2.4%, per the market data section.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $305.1M | $16.0M | $7.5M | N/A | $15.7M | $496.0M | $57.2M |
| FY 2024 | $152.6M | $-47.1M | $-41.6M | N/A | $-46.8M | $191.5M | $51.5M |
| FY 2023 | $71.7M | $-69.5M | $-82.7M | N/A | $-56.9M | N/A | $697.4M |
Per the SEC financials, revenue grew from $71.7M (FY 2023) to $305.1M (FY 2025), and the company moved from operating losses to a reported operating income of $16.0M in FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 22.24 and the Piotroski F-Score is 9/9, while the market data section reports ROIC of 2.9% and a Debt/Equity of 0.12 within the forensic pillar. Reported FY 2025 cash of $496.0M exceeds reported debt of $57.2M.
Recent Catalysts & News Wire Analysis
- Seeking Alpha (YELLOW, MARKET WIRE): a report on market action, institutional positioning, and fundamental catalysts, framed around quality and GARP credentials.
- Investing.com (YELLOW, MARKET WIRE): a report that the CTO sold $2.16M in shares.
- Stock Titan (YELLOW, MARKET WIRE): a report that a $4.45M sale was followed by a proposal to sell more shares.
- MarketBeat (RED, RISK WATCH): a report that the stock fell 6.5%.
- Simply Wall St (YELLOW, MARKET WIRE): a stock forecast and analyst predictions report.
- MarketBeat (GREEN, CATALYST): a report that the stock rose 3.5%.
The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.
Open Questions
- What are BillionToOne's products, customers, and revenue model, given the source data provides only sector and industry labels?
- What explains the gap between reported FY 2025 net income of $7.5M and the 0.29% FCF yield at a $5.42B market cap?
- What is the basis for the reported FY 2023 cash figure being N/A while FY 2023 debt is $697.4M, and how did debt decline to $57.2M?
- What are the trailing and forward earnings per share, which the source data does not provide?
- What do the insider sales cited in the news wire represent relative to total holdings, and do they reflect scheduled or discretionary activity?
BLLN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for BillionToOne Inc. (BLLN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 19h ago
BillionToOne: Molecular Diagnostics Stock With Strong Quality And GARP Credentials (BLLN) Seeking Alpha report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 22h ago
BillionToOne CTO David Tsao sells $2.16m in shares Investing.com report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
After a $4.45M sale, Atay proposes selling more BillionToOne (BLLN) shares. Stock Titan report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH MarketBeat • 1d ago
Billiontoone (NASDAQ:BLLN) Stock Falls 6.5% - What's Next? MarketBeat report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
BillionToOne (NasdaqGS:BLLN) Stock Forecast & Analyst Predictions Simply Wall St report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
Billiontoone (NASDAQ:BLLN) Stock Jumps 3.5% - Here's What Happened MarketBeat report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 20,000-share option exercise accompanies a proposed sale by a BillionToOne (NASDAQ: BLLN) officer. Stock Titan report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share (BLLN) Seeking Alpha report covering BillionToOne Inc. (BLLN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BLLN Bull vs. Bear Conversation Board — What's Your Call at $113.32?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLLN 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $135.51 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BLLN (B- • RQD 71/100) a Buy at $114.84?
Welcome to the BLLN (BillionToOne Inc.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy — Sound Institutional Accumulation) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $89.58 (-22.0%)
Spot @ $114.84 Pump the brakes on BLLN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BLLN, but look at what you are paying: current EV/EBITDA multiples with 68.3% gross margins. Unless BillionToOne Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $143.55 (+25.0%)
Spot @ $114.84 BLLN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BLLN, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $114.84 (52-wk range $61.96 - $150.44), any beat on forward guidance forces shorts and underweight funds to chase.